NVCR News and Press, NovoCure Limited From 07/27/23

2023-07-27 18:56:08 ET Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure 's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by almost 16% on the day due to worse-than-expected fundamentals f...

2023-07-27 11:30:26 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2023 Earnings Call Jul 27, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2023 Earnings Call Transcript

2023-07-27 07:11:47 ET NovoCure press release ( NASDAQ: NVCR ): Q2 GAAP EPS of -$0.54 misses by $0.04 . Revenue of $126.05M (-10.5% Y/Y) beats by $1.8M . 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer ...

Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024 Interim analysis for fu...

2023-07-26 12:27:10 ET NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q2 earnings results on Thursday, July 27th, before market open. The consensus EPS Estimate is -$0.50 and the consensus Revenue Estimate is $124.25M (-11.8% Y/Y). Over the last 2 years, NVCR has...

2023-07-25 17:09:58 ET Summary In early June, NovoCure's stock dropped 43% in a single day after the company presented the LUNAR study at ASCO. The stock now trades near 5-year lows. What caused the drop exactly? And is this the end of the story for NovoCure? The details of th...

New York, New York--(Newsfile Corp. - July 25, 2023) - Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: NovoCure Limited (NASDAQ: NVCR) NovoCure is a global oncology company with a proprietary platform technology c...

2023-07-22 05:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Economic resiliency, s...

Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and ...

MOORE KUEHN ANNOUNCES ENCOURAGES NOVOCURE LIMITED INVESTORS TO CONTACT LAW FIRM PR Newswire NEW YORK , July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ...